Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Korosho Proposes More Fees for Treatment of Mental Illness
November 5, 2007
-
ARCHIVE Chugai to Place Top Priority on Proper Use of Tarceva
November 5, 2007
-
ARCHIVE Korosho to Order Revision of Package Insert for All Antidepressants
November 5, 2007
-
ARCHIVE Chugai's Operating Profits Up 24% in First 3 Qtr
November 5, 2007
-
ARCHIVE Telavancin Received FDA Approvable Letter: Astellas
November 5, 2007
-
COLUMN Maurer's Healthcare Insight (90)
November 5, 2007
-
ARCHIVE Nexavar, Zevalin, Gracevit, Prezista Recommended for Approval
November 5, 2007
-
ARCHIVE SEMINAR
November 5, 2007
-
ARCHIVE Lonasen, Clexane, Amage Recommended for Approval
November 5, 2007
-
ARCHIVE Korosho Found to Have Identifying Information on 118 Hepatitis C Patients
November 5, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
November 5, 2007
-
ARCHIVE Gastric Cancer GL Stress Use of TS-1 for Inoperable Patients
November 5, 2007
-
ARCHIVE Kirin HD-Kyowa Hakko Deal Beneficial for Kirin HD, Neutral for Kyowa Hakko's Shareholders: DIR Report
November 5, 2007
-
ARCHIVE Defensive Factor Enhancing Agents Not Recommended after Endoscopic Therapy
November 5, 2007
-
ARCHIVE Mr Sekiguchi Explains PhRMA's Stance Regarding NHI Pricing
November 5, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
November 5, 2007
-
ARCHIVE Novartis to Cut 1,260 Jobs in the US
November 5, 2007
-
ARCHIVE Paltac to Stimulate OTC Drug Market by Merging with Kobashou
October 29, 2007
-
ARCHIVE MR Education Center Considers Radical Reform of MR Education System
October 29, 2007
-
ARCHIVE R&D NEWS IN BRIEF
October 29, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…